CSI Market
Sign In | Register

Panacea Life Sciences Holdings Inc (EXDI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EXDI Annual Cash Flow →
From Panacea Life Sciences Holdings Inc through Mar 31 2023, changes in Mar 31 2024's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-1.45
Depreciation & amortization0.38
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.05
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Debt Instrument Decrease Forgiveness-
Marketable Securities Realized Gain Loss Other Than Temporary Impairments Amount-
Interest Expense-
Derivative Cost Of Hedge-
Stock Issued During Period Shares Other-
Officer And Director Stock Payment-
Warrant Expense-
Derivative Gain Loss On Derivative-
Amortization Of Prepaid Stockbased Expenses-
Advances To Supplier Related Party-
Operating Lease Right Of Use Asset Amortization Expense-
Gains Losses On Settlement Of Debt-
Increase Decrease Unearned Revenues-
Non Cash Settlement Of Convertible Note And Accrued Interest-
Marketable Securities Unrealized Gain Loss-
Increase Decrease In Operating Lease Liability0.14
Marketable Securities Unrealized Gain Losses0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.01
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.55
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.07
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.36
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Proceeds from Previous Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.45
Long-term debt - repayments-0.08
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.10
Proceeds From Issuance Of Preferred Stock Series D Stock-
Proceeds From Issuance Of Preferred Stock And Preference Stock-
Increase Decrease In Due To Related Party Classified As Equity-
Proceeds From Notes Payable Related Party-
Proceeds From Non Cash Stock Issuances-
Proceeds From Payroll Protection S B A Loans-
Proceeds From Payroll Protection Loan Related Party-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations0.10
Proceeds From Payroll Protection Loan Sba Loan-
Repayment Of Notes Payable-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.37
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.36
Total Cash Flow0.01
4 historic quarters locked

Sign in to unlock the full Panacea Life Sciences Holdings Inc cash flow history.

Sign In Create Free Account

About Panacea Life Sciences Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240331)
  • Filed with the SEC: May 6, 2024
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-24-017858

Figures are derived from filed reports and may be restated. Historical data is subject to revision.